James Baroutas of New York, New York, a stockbroker registered with B. Riley Wealth Management, is the subject of a customer initiated investment related Financial Industry Regulatory Authority (FINRA) securities arbitration claim in which the customer requested $300,000.00 in damages based upon allegations that Baroutas engaged in unauthorized trading and other misconduct in connection with the purchase and sale of certain securities including IN8Bio, Eloxx Pharmaceutical, Journey Medical, Runway Growth, Landsea Homes, Cadiz, Doubledown Interactive LifeMD, and Minim. FINRA Arbitration No. 22-01595 (July 18, 2022).
FINRA Public Disclosure shows that Baroutas is referenced in other customer initiated investment related disputes while associated with securities broker dealers, including SBC Warburg Dillon Read Inc. On January 8, 1993, a customer initiated investment related FINRA securities arbitration claim involving Baroutas’ conduct was settled for $55,000.00 in damages based upon allegations that Baroutas made unsuitable investment recommendations in connection with the sale of investments. FINRA Arbitration No. 91-03115.
On April 14, 1998, a securities arbitration claim involving Baroutas’ conduct was settled for $49,500.00 in damages based upon allegations that Baroutas committed sales practice violations with regard to the recommendation and sale of investments when Baroutas was associated with SBC Warburg Dillon Read Inc. NASD Arbitration No. 98-02537.
James Baroutas has been associated with B. Riley Wealth Management since January 20, 2015.